

Biotechnology
that Changes The Future

Medytox

Medytox is
a biopharmaceutical company
that changes the future
with ceaseless R&D




Medytox R&D Center (Gwanggyo)
1322-8, Iui-dong, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea

Overview	4
History	10
Performance	12
Products	16
R&D	26
Plants	30
Contact Information	36

Medytox

at a Glance



Growing as a **global leader** in the medical aesthetic field

The only biopharmaceutical company in the world to have three different types of botulinum toxin product (Neuronox[®], INNOTOX[®], Coretox[®]), all developed by in-house R&D

- 1 First company in Korea and fourth company worldwide to develop a botulinum toxin type A product
- 2 Development of the world's first liquid formulation of botulinum toxin type A product with no animal-derived ingredients
- 3 Development of purified botulinum toxin type A product, which contains only the core active ingredient, and no animal-derived substances

Development of various hyaluronic acid dermal fillers from in-house R&D



Expanding beyond domestic boundaries

For our international business, Medytox has one sales force subsidiary in Japan. We also set up 4 Joint Venture companies in China, Taiwan, Thailand and Hong Kong for direct penetration





Beginning

- 2000** — • Medytox Established
- 2001** — • Established the Microbial Toxin R&D Center at Medytox
- 2004** — • Obtained KGMP Approval for Medytox Plant I(Ochang)
- 2006** — • Obtained Marketing Approval from KFDA for Neuronox®
 - Selected as 'World-class product' for Neuronox®

Growth

- 2007** — • Opened Medytox Seoul office
- 2008** — • Selected as 'Bio Star Enterprise'
- 2009** — • Listed on KOSDAQ
 - Obtained Marketing Approval from KFDA for Neuronox® 200U
 - Achieved No.1 Market Share in the Botulinum Toxin Market in Korea
- 2010** — • Obtained Marketing Approval from KFDA for Neuronox® 50U
- 2011** — • Selected as an Advanced Technology Center(ATC)
 - Obtained KGMP Approval for HA Dermal Filler facility in Medytox Plant I
 - Received CE marking (Conformité Européenne) for Neuramis® Deep
- 2012** — • Selected as 'Innovative Pharmaceutical Company Accreditation'
- 2013** — • Established Medytox Korea (Subsidiary for domestic sales)
 - Opened Medytox US Office
 - Obtained Marketing Approval from MFDS (Formerly KFDA) for Neuramis® Deep
 - Signed a License Agreement with Allergan for new formulation of Botulinum Toxin type A product
 - Obtained Marketing Approval from MFDS for Neuronox® 150U
 - Obtained Marketing Approval from MFDS for INNOTOX®
- 2014** — • Completed Medytox Plant II(Osong) Construction (cGMP/EU GMP)
 - Selected as the K-Brain Power Company
 - Obtained Marketing Approval from MFDS for Neuramis® Deep Lidocaine




Take - off

- 2015** — • Established Joint Ventures, including Medytox Taiwan, MedyBloom China, Medytox Hong Kong
 - Established Medytox Japan(MDT International), a subsidiary in Japan
 - Obtained Marketing Approval from MFDS for Neuramis® Lidocaine Series
 - Obtained Marketing Approval from MFDS for INNOTOX® 50U
- 2016** — • Obtained Marketing Approval from MFDS for Coretox® 100U
 - Obtained KGMP Approval for Medytox Plant III(Osong)
- 2017** — • Relocated to Medytox Global Business Center(Seoul)
 - Established MedyCeles, a JV in Thailand
 - Completed Medytox R&D Center (Gwanggyo) Construction
- 2018** — • Began phase 3 trials of new formulation of Botulinum Toxin type A product in US, Canada by Allergan Inc.
 - Received the presidential commendation award at the 2018 Governor's Job Creation Awards
 - Selected as '2018 the Best Job Creation Company in Korea'
 - Neuronox and Neuramis, selected as 'Korean World-class Products Awards 2018'
 - Started Global CSR Campaign 'Team 2022'
 - Received \$100M Export Tower Award


Growth is
the word that best
summarizes the past
5 years of **Medytox**

During this period, we achieved 52% CAGR with over average 50% operating income rate.



Medytox has
ranked **No.1** in
its market share
in Korea since 2009

Our market share remarkably has been increased from an initial 8% to over 50%.



Product

Neuronox®
Botulinum Toxin Type A Complex
INNOTOX®
Coretox®
Neuramis®



[Rx Only]

Neuronox®

The First Choice
of Botulinum Toxin Type A

The first botulinum toxin type A product
developed in Korea

Sold over 12 million vials worldwide

- Since 2006

**Comparable efficacy
with BOTOX®**

- Efficacy and safety proven in clinical studies



Neuronox® is a standard version of botulinum toxin type A product.

Given its proven efficacy and safety, it is offering a more affordable option than the competition. The product is registered in 32 countries. (Being sold worldwide under different brand names including Sialax®, Botulift®, Cunox®, Acebloc® and Meditoxin®)

Since its launch in 2006, Neuronox® became the No.1 selling product in Korea and Thailand.

It is sold over 12 million vials worldwide.*

** Figures from Medytox (2018.12)*

[Rx Only]

INNOTOX[®]

The Innovation
of Botulinum Toxin Type A

**The world's first liquid formulation of
botulinum toxin type A product**

Advanced safety

- No animal derived component
- No HSA

Convenience

- Premixed
- Easy to use



INNOTOX[®] is the first liquid formulation of botulinum toxin type A product.

INNOTOX[®] comes as a pre-mixed so the concentration of the solution is consistent. By excluding the process of mixing saline, this reduces the chance of human error and improves the dosage accuracy. As for safety, we have excluded animal sources and human serum albumin. Without involving saline reconstitution, it absolutely eliminates any chance of contamination.

Currently INNOTOX[®] is being sold in Korea and Japan.

[Rx Only]

CORETOX[®]

The New
of Botulinum Toxin Type A

**The first pure botulinum toxin
type A product developed in Korea**

Less immune response

- Free of accessory protein

Advanced safety

- No animal derived component
- No HSA



Coretox[®] is an advanced new botulinum toxin type A product.

Coretox[®] has less immune response to human bodies due to free of accessory proteins. Also, it excludes animal derivatives and Human Serum Albumin which makes it safer than the competition from its ingredients. It has less immune response to human bodies due to free of accessory proteins.

Currently Coretox[®] is being sold in Korea.



Neuramis®

The Smart Choice
of Hyaluronic Acid Dermal Filler

Enhanced Safety

- Using high quality HA registered in FDA and EDQM

Long lasting Effect


- Performing double crosslinking

High Satisfaction

- Maintaining a natural look after injection

Easy to use

- Ideal properties developed scientifically



Neuramis® is the hyaluronic acid dermal filler products all developed by in-house R&D.

Neuramis® became the No.1 domestic HA filler in Korea since 2017. The reason for this is due to the products safety. We have removed almost all of the BDDE which is a crosslinking agent from the product. This has drastically reduced the negative side effects like itching and edema. In addition to make the product safer, we have added an extra layer of precaution. We exposed our finished product to an autoclave system which is something our competitors are not doing. We achieved 100% sterilization using heat with zero defects.

Currently Neuramis® is registered in 24 countries.





R & D

R&D Center
R&D
Plant

Biotechnology

that changes the future

Medytox shows biotechnology that changes the future through innovative technology and differentiated R&D.

R&D Accomplishments

- 1 First In-house development of 3 types of botulinum toxin, each with unique strengths in the world.
- 2 Development of various hyaluronic acid filler with distinct technology
- 3 Signed a License Agreement between Allergan Inc.(US) for new formulation of new botulinum toxin type A product

Medytox has been working towards the vision of growing as a global biotech company. By utilizing infrastructure and biopharmaceutical development capacity built from botulinum toxin pharmaceutical development, we generate profit and reinvest it in developing innovative biopharmaceuticals. With the goal of success in developing new bio pharmaceuticals in the near future, we are cooperating with external R&D partners.

Medytox is continually growing as a global biotech company through continuous product development and investment.

Medytox R&D Center

Moving beyond Korea, Medytox aims to be the No.1 biopharmaceutical company globally.



Who knows botulinum toxin better than Medytox?

Medytox's biotechnology competitiveness

- 1 World-class R&D capacity and infrastructure for microbial toxin biopharmaceutical products
- 2 Participation in various government-led R&D projects on botulinum toxin biopharmaceutical products
- 3 World-class botulinum toxin R&D team
- 4 Expansion of R&D to cover the development of various medical aesthetics products, including the development of a hyaluronic acid dermal filler
- 5 Continuous R&D investments for the development of new biopharmaceutical products



Botulinum toxin, one of the neurotoxins produced by *Clostridium botulinum*, is known as the most toxic substance in nature. It is widely used not only in the medical aesthetics field, including facial wrinkle reduction, but also in the therapeutic field for patients with blepharospasm, strabismus, cerebral palsy, etc.

As the first botulinum toxin developer and the market leader in Korea, Medytox feels a sense of pride and responsibility for leading the botulinum toxin industry. So Medytox is making efforts to improve the transparency and the competitiveness of the global biopharmaceutical businesses by pushing the implementation of more objective and scientific guidelines for industry practice.

Additionally, by maintaining its focus on continual in-house R&D, Medytox has developed three different types of botulinum toxin products, Neuronox[®], INNOTOX[®] and Coretox[®], each with its own unique strengths. Medytox are stepping up our efforts to enter the advanced markets as well as penetrate directly to emerging markets. Additionally, we will continue to increase the R&D investment, develop new businesses, and always seek new acquisition opportunities to create synergy.

Medytox strongly believes that these continued efforts and passion to develop biotechnology will help to create more advanced, healthier, and happier lives for everyone.

Medytox Plant I

78, Gangni 1-gil, Ochang-eup,
Cheongwon-gu, Cheongju-si,
Chungcheongbuk-do, Republic of Korea



Medytox Plant I (Ochang), Korea's first botulinum toxin type A manufacturing facility, is producing 60 billion KRW worth of botulinum toxin type A and 0.1 trillion KRW worth of hyaluronic acid filler annually.



Medytox Plant I (Ochang), a botulinum toxin and HA filler manufacturing facility, obtained GMP approval for biologics and injectable from MFDS (Formerly KFDA) in 2004.

This plant was designed as a dedicated facility for manufacture of the botulinum toxin, as well as the final product. HA Filler production facility received ISO13485 (medical device) approval in 2010.

Medytox Plant I is deeply committed to the manufacturing of highest quality products for consumers everywhere.



Medytox Plant II

78, Gangni 1-gil, Ochang-eup,
Cheongwon-gu, Cheongju-si,
Chungcheongbuk-do, Republic of Korea

Medytox Plant II (Osong), designed to meet cGMP of US FDA and GMP standard of European EMA, can produce more than 500 billion KRW worth of botulinum toxin Type A product.

Currently, it is operated as a production facility for new botulinum toxin type A(Nivobotulinum toxin A) for Allergan Inc. (USA).



Medytox, with global expansion in mind, established the Medytox Plant II (Osong), which is dedicated to toxin production for the penetration of the U.S. and the European markets.

The plant started to produce samples of new botulinum toxin type A(Nivobotulinum toxin A) and we shipped the samples to Allergan Inc. for phase 3 clinical studies in 2018.

Medytox Plant II will play a leading role in producing and supplying innovative botulinum toxin products intended for the global market.




Medytox Plant III

102, Osongsaengmyeong 4-ro, Yeonje-ri,
Osong-eup, Heungdeok-gu, Cheongju-si,
Chungcheongbuk-do, Republic of Korea



Medytox Plant III (Osong), designed and built to produce annual sales 0.6 trillion KRW worth of botulinum toxin type A and 0.5 trillion KRW worth of filler product, is running to accommodate global product demands.



Medytox plant III at Osong obtained KGMP approval for toxin facility in 2016.

Medytox Plant III is a cGMP/ EU GMP compliant facility for production of both botulinum toxin product and HA filler. It will supplement the production quantity to meet the increasing market demand and provide additional capacity to allow for the entry into developed markets such as the US and the EU.



Contact Information

Medytox Plant I (Ochang)

78, Gangni 1-gil, Ochang-eup,
Cheongwon-gu, Cheongju-si,
Chungcheongbuk-do, Republic of Korea
T 043 217 1555
F 043 217 1557

Medytox Plant II (Osong)

71, Osongsaengmyeong 6-ro, Mansu-ri,
Osong-eup, Heungdeok-gu, Cheongju-si,
Chungcheongbuk-do, Republic of Korea
T 043 217 1555
F 043 217 1557

Medytox Plant III (Osong)

102, Osongsaengmyeong 4-ro, Yeonje-ri,
Osong-eup, Heungdeok-gu, Cheongju-si,
Chungcheongbuk-do, Republic of Korea
T 043 217 1555
F 043 217 1557

Medytox Global Business Center

Medytox Bldg., 626, Teheran-ro,
Gangnam-gu, Seoul, Republic of Korea
T 02 3471 8319
F 02 3476 8372

Medytox Korea Seoul Office

F8, 626, Teheran-ro, Gangnam-gu,
Seoul, Republic of Korea
T 080 850 2006
F 02 535 8334

Medytox US Office

20271, Goldenrod Lane, suite 2080/2082,
Germantown, MD, 20876
T +1 301 972 0810
F +1 301 972 0682

MDT International (Japan)

6F, HamamatsuchoWest BLDG, 2-10-4,
Shibakoen, Minato-ku, Tokyo, Japan
T +81 3 6452 9606
F +81 3 6452 9608

Medytox R&D Center (Osong)

71, Osongsaengmyeong 6-ro, Mansu-ri,
Osong-eup, Heungdeok-gu, Cheongju-si,
Chungcheongbuk-do, Republic of Korea
T 043 217 1555
F 043 217 1557

Medytox R&D Center (Gwanggyo)

1322-8, Iui-dong, Yeongtong-gu,
Suwon-si, Gyeonggi-do, Republic of Korea
T 070 8666 7796
F 043 217 1557

Medytox is
a biopharmaceutical company
that changes the future
with ceaseless R&D

For more information, visit www.medytox.com



www.medytox.com